WO2022197720A3 - Compositions and methods for treating coronavirus infection - Google Patents

Compositions and methods for treating coronavirus infection Download PDF

Info

Publication number
WO2022197720A3
WO2022197720A3 PCT/US2022/020407 US2022020407W WO2022197720A3 WO 2022197720 A3 WO2022197720 A3 WO 2022197720A3 US 2022020407 W US2022020407 W US 2022020407W WO 2022197720 A3 WO2022197720 A3 WO 2022197720A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
coronavirus
coronavirus infection
methods
treating coronavirus
Prior art date
Application number
PCT/US2022/020407
Other languages
French (fr)
Other versions
WO2022197720A2 (en
Inventor
Dan H. Barouch
Bette T. Korber
James Theiler
Original Assignee
Beth Israel Deaconess Medical Center, Inc.
Triad National Security, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center, Inc., Triad National Security, Llc filed Critical Beth Israel Deaconess Medical Center, Inc.
Priority to CA3177045A priority Critical patent/CA3177045A1/en
Publication of WO2022197720A2 publication Critical patent/WO2022197720A2/en
Publication of WO2022197720A3 publication Critical patent/WO2022197720A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are immunogenic compositions and vaccines containing rationally designed coronavirus Spike proteins and polynucleotides encoding the same that can be administered to treat or inhibit a coronavirus infection. The compositions and vaccines can also be used to produce anti-coronavirus antibodies (e.g., broadly neutralizing anti-coronavirus antibodies), which can also be used for prophylactic or therapeutic purposes in the treatment of a coronavirus infection.
PCT/US2022/020407 2021-03-15 2022-03-15 Compositions and methods for treating coronavirus infection WO2022197720A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3177045A CA3177045A1 (en) 2021-03-15 2022-03-15 Compositions and methods for treating coronavirus infection

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163161318P 2021-03-15 2021-03-15
US63/161,318 2021-03-15
US202163256848P 2021-10-18 2021-10-18
US63/256,848 2021-10-18

Publications (2)

Publication Number Publication Date
WO2022197720A2 WO2022197720A2 (en) 2022-09-22
WO2022197720A3 true WO2022197720A3 (en) 2022-12-22

Family

ID=83322336

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/020407 WO2022197720A2 (en) 2021-03-15 2022-03-15 Compositions and methods for treating coronavirus infection

Country Status (2)

Country Link
CA (1) CA3177045A1 (en)
WO (1) WO2022197720A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235763A1 (en) 2022-06-02 2023-12-07 Vector Sciences, Inc. Method of reducing adenoviral vector-associated tts
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
WO2024050482A2 (en) * 2022-08-31 2024-03-07 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for treating coronavirus infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2021168577A1 (en) * 2020-02-25 2021-09-02 Symvivo Corporation Gene delivery system
WO2022051859A1 (en) * 2020-09-11 2022-03-17 Manuel Caruso Pseudotyped retroviral particles for inducing immunity against coronavirus infections

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168577A1 (en) * 2020-02-25 2021-09-02 Symvivo Corporation Gene delivery system
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2022051859A1 (en) * 2020-09-11 2022-03-17 Manuel Caruso Pseudotyped retroviral particles for inducing immunity against coronavirus infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DENG, X ET AL.: "Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation", MEDRXIV, 9 March 2021 (2021-03-09), pages 1 - 47, XP093018609, DOI: 10.1101/ 2021.03.07.21252647 *
GRABOWSKI, F ET AL.: "L18F substrain of SARS CoV 2 VOC 202012/01 is rapidly spreading in England", MEDRXIV, 9 February 2021 (2021-02-09), pages 1 - 7, XP093018608, DOI: 10.1101/ 2021.02.07.21251262 *

Also Published As

Publication number Publication date
CA3177045A1 (en) 2022-09-22
WO2022197720A2 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
WO2022197720A3 (en) Compositions and methods for treating coronavirus infection
MX2023000411A (en) Sars-cov-2 and influenza combination vaccine.
MX2022009460A (en) Coronavirus vaccine.
MX2020010941A (en) Novel rsv rna molecules and compositions for vaccination.
MX2018014573A (en) Zika virus vaccine.
MX2023007574A (en) Rna vaccine against sars-cov-2 variants.
MX2010006519A (en) Method for treating bone fracture with anti-sclerostin antibodies.
MX2019012884A (en) Combination therapy.
MX2018015506A (en) Vaccine against infectious bronchitis virus.
MX2022010186A (en) Botulinum neurotoxins for use in therapy.
MX2023011035A (en) Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy.
MX2023004156A (en) Combination therapy for treating cancer.
MX2021002349A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack.
BR112022013646A2 (en) METHOD OF TREATMENT OF SPLENOMEGALY
EP1471936A4 (en) Hiv vaccine and method of use
MX2023012368A (en) Virus vaccine.
WO2022192594A3 (en) Nucleic acid molecules and vaccines comprising same for the prevention and treatment of coronavirus infections and disease
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
MX2021008716A (en) Method for treating osteoarthritis pain by administering resiniferatoxin.
MX2020013601A (en) Cancer-specific t-cell receptors.
MX2023002757A (en) Pharmaceutical combination and tumor treatment.
WO2022010813A3 (en) Enhancing immune responses through targeted antigen expression
EP4295862A3 (en) Coronavirus vaccine
WO2024050482A3 (en) Compositions and methods for treating coronavirus infection
MX2022015438A (en) Dispersible tablet formulations comprising dolutegravir.

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3177045

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22772073

Country of ref document: EP

Kind code of ref document: A2